Specific and strain-independent effects of dexamethasone in the prevention and treatment of experimental autoimmune encephalomyelitis in rodents

Scandinavian Journal of Immunology

Volumn 72, Issue 5, 2010, Pages 396-407

  Donia, M ^a   Mangano, K ^a   Quattrocchi, C ^a   Fagone, P ^a   Signorelli, S ^a   Magro, G ^a   Sfacteria, A ^b   Bendtzen, K ^c   Nicoletti, F ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c Rigshospitalet   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE SODIUM PHOSPHATE; GAMMA INTERFERON; MYELIN BASIC PROTEIN; PROTEOLIPID PROTEIN;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CLINICAL FEATURE; CONTROLLED STUDY; CORTICOSTEROID THERAPY; CYTOKINE RELEASE; DARK AGOUTI RAT; DBA MOUSE; DISEASE MODEL; FEMALE; HISTOPATHOLOGY; IN VIVO STUDY; LEWIS RAT; MALE; MONONUCLEAR CELL; MOUSE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; RAT; SPINAL CORD; STRAIN DIFFERENCE; SWISS JACKSON LABORATORIES MOUSE; TISSUE HOMOGENATE; WEIGHT REDUCTION;

ANIMALS; BODY WEIGHT; DEXAMETHASONE; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; GLUCOCORTICOIDS; HUMANS; INTERFERON-GAMMA; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; MICE, INBRED STRAINS; RATS; RATS, INBRED LEW; RATS, INBRED STRAINS; SPECIES SPECIFICITY; SPINAL CORD; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 77958111208     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2010.02451.x     Document Type: Article

References (65)

1. Milo R, Kahana E. Multiple sclerosis: geoepidemiology, genetics and the environment. Autoimmun Rev 2010;9:A387-94.
2. Holmøy T, Vartdal F. The immunological basis for treatment of multiple sclerosis. Scand J Immunol 2007;66:374-82.
3. Multiple Sclerosis Therapy Consensus Group (MSTCG). Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations. J Neurol 2008;255:1449-63.
4. Namaka M, Crook A, Doupe A etal. Examining the evidence: complementary adjunctive therapies for multiple sclerosis. Neurol Res 2008;30:710-9.
5. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907-11.
6. Martinelli Boneschi F, Rovaris M, Capra R, Comi G. Mitoxantrone for multiple sclerosis. Cochrane Database Syst Rev 2005;4:CD002127.
7. Martinelli V, Radaelli M, Straffi L, Rodegher M, Comi G. Mitoxantrone: benefits and risks in multiple sclerosis patients. Neurol Sci 2009;30 (Suppl. 2):S167-70.
8. Rinaldi L, Perini P, Calabrese M, Gallo P. Cyclophosphamide as second-line therapy in multiple sclerosis: benefits and risks. Neurol Sci 2009;30 (Suppl. 2):S171-3.
9. Ait Ben Haddou E, Benomar A, Ahid S etal. Efficacy and safety of cyclophosphamide treatment in progressive multiple sclerosis. Rev Neurol (Paris) 2009;165:1086-91.
10. Lassmann H, Brück W, Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med 2001;7:115-21.
11. Becanovic K, Jagodic M, Wallström E, Olsson T. Current gene-mapping strategies in experimental models of multiple sclerosis. Scand J Immunol 2004;60:39-51.
12. Centola M, Frank MB, Bolstad AI etal. Genome-scale assessment of molecular pathology in systemic autoimmune diseases using microarray technology: a potential breakthrough diagnostic and individualized therapy-design tool. Scand J Immunol 2006;64:236-42.
13. Barnett MH, Parratt JD, Pollard JD, Prineas JW. MS: is it one disease? Int MS J 2009;16:57-65.
14. Weiner HL. The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease? Ann Neurol 2009;65:239-48.
15. Mix E, Meyer-Rienecker H, Zettl UK. Animal models of multiple sclerosis for the development and validation of novel therapies - potential and limitations. J Neurol 2008;255 (Suppl. 6):7-14.
16. Wekerle H. Lessons from multiple sclerosis: models, concepts, observations. Ann Rheum Dis 2008;67 (Suppl. 3):iii56-60.
17. Basso AS, Frenkel D, Quintana FJ etal. Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis. J Clin Invest 2008;118:1532-43.
18. Abdul-Majid KB, Jirholt J, Stadelmann C etal. Screening of several H-2 congenic mouse strains identified H-2(q) mice as highly susceptible to MOG-induced EAE with minimal adjuvant requirement. J Neuroimmunol 2000;2:23-33.
19. Sriram S, Steiner I. Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis. Ann Neurol 2005;58:939-45.
20. Steinman L, Zamvil SS. How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann Neurol 2006;60:12-21.
21. Mangano K, Nicoletti A, Patti F etal. Variable effects of cyclophosphamide in rodent models of experimental allergic encephalomyelitis. Clin Exp Immunol 2010;159:159-68.
22. Chavarria A, Alcocer-Varela J. Is damage in central nervous system due to inflammation? Autoimmun Rev 2004;3:251-6.
23. Payne N, Siatskas C, Bernard CC. The promise of stem cell and regenerative therapies for multiple sclerosis. J Autoimmun 2008;31:288-94.
24. Frohman EM, Shah A, Eggenberger E, Metz L, Zivadinov R, Stuve O. Corticosteroids for multiple sclerosis: I. Application for treating exacerbations. Neurotherapeutics 2007;4:618-26.
25. Myhr KM, Mellgren SI. Corticosteroids in the treatment of multiple sclerosis. Acta Neurol Scand Suppl 2009;189:73-80.
26. Sorensen PS, Mellgren SI, Svenningsson A etal. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial. Lancet Neurol 2009;8:519-29.
27. Nguyen KB, McCombe PA, Pender MP. Increased apoptosis of T lymphocytes and macrophages in the central and peripheral nervous systems of Lewis rats with experimental autoimmune encephalomyelitis treated with dexamethasone. J Neuropathol Exp Neurol 1997;56:58-69.
28. Nagai H, Goto M, Kamada H, Boda K, Kitagaki K, Takaoka Y. Immunopharmacological studies on experimental allergic encephalomyelitis in DA rats. Gen Pharmacol 1998;30:161-6.
29. Agnello D, Carvelli L, Muzio V etal. Increased peripheral benzodiazepine binding sites and pentraxin 3 expression in the spinal cord during EAE: relation to inflammatory cytokines and modulation by dexamethasone and rolipram. J Neuroimmunol 2000;109:105-11.
30. Chan J, Ban EJ, Chun KH etal. Methylprednisolone induces reversible clinical and pathological remission and loss of lymphocyte reactivity to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis. Autoimmunity 2008;41:405-13.
31. Wüst S, Van Den Brandt J, Tischner D etal. Peripheral T cells are the therapeutic targets of glucocorticoids in experimental autoimmune encephalomyelitis. J Immunol 2008;180:8434-43.
32. Chen X, Hu X, Zou Y etal. Combined treatment with minocycline and prednisone attenuates experimental autoimmune encephalomyelitis in C57 BL/6 mice. J Neuroimmunol 2009;210:22-9.
33. Miljković Z, Momcilović M, Miljković D, Mostarica-Stojković M. Methylprednisolone inhibits IFN-gamma and IL-17 expression and production by cells infiltrating central nervous system in experimental autoimmune encephalomyelitis. J Neuroinflammation 2009;11:6-37.
34. St Louis J, Uniyal S, Xu L etal. Tolerance induction by acylated peptides: suppression of EAE in the mouse with palmitoylated PLP peptides. J Neuroimmunol 2001;115:79-90.
35. Ahlem C, Auci D, Mangano K etal. HE3286: a novel synthetic steroid as an oral treatment for autoimmune disease. Ann N Y Acad Sci 2009;1173:781-90.
36. Abdul-Majid KB, Stefferl A, Bourquin C etal. Fc receptors are critical for autoimmune inflammatory damage to the central nervous system in experimental autoimmune encephalomyelitis. Scand J Immunol 2002;55:70-81.
37. Abdul-Majid KB, Wefer J, Stadelmann C etal. Comparing the pathogenesis of experimental autoimmune encephalomyelitis in CD4-/- and CD8-/- DBA/1 mice defines qualitative roles of different T cell subsets. J Neuroimmunol 2003;2:10-9.
38. Wållberg M, Harris RA. Co-infection with Trypanosoma brucei prevents experimental autoimmune encephalomyelitis in DBA/1 mice through induction of suppressor APCs. Int Immunol 2005;17:721-8.
39. Di Marco R, Puglisi G, Papaccio G etal. Sodium fusidate (fusidin) ameliorates the course of monophasic experimental allergic encephalomyelitis in the Lewis rat. Mult Scler 2001;7:101-4.
40. Besong G, Battaglia G, D'Onofrio M etal. Activation of group III metabotropic glutamate receptors inhibits the production of RANTES in glial cell cultures. J Neurosci 2002;22:5403-11.
41. Di Marco R, Khademi M, Wallstrom E etal. Curative effects of recombinant human Interleukin-6 in DA rats with protracted relapsing experimental allergic encephalomyelitis. J Neuroimmunol 2001;116:168-77.
42. Di Marco R, Mangano K, Quattrocchi C, Amato F, Nicoletti F, Buschard K. Exacerbation of protracted-relapsing experimental allergic encephalomyelitis in DA rats by gluten-free diet. APMIS 2004;112:651-5.
43. Donia M, Mangano K, Amoroso A etal. Treatment with rapamycin ameliorates clinical and histological signs of protracted relapsing experimental allergic encephalomyelitis in Dark Agouti rats and induces expansion of peripheral CD4+CD25+Foxp3+ regulatory T cells. J Autoimmun 2009;33:135-40.
44. Reichardt HM, Gold R, Lühder F. Glucocorticoids in multiple sclerosis and experimental autoimmune encephalomyelitis. Expert Rev Neurother 2006;6:1657-70.
45. O'Neill EJ, Day MJ, Wraith DC. IL-10 is essential for disease protection following intranasal peptide administration in the C57BL/6 model of EAE. J Neuroimmunol 2006;178:1-8.
46. Lorentzen JC, Issazadeh S, Storch M etal. Protracted, relapsing and demyelinating experimental autoimmune encephalomyelitis in DA rats immunized with syngeneic spinal cord and incomplete Freund's adjuvant. J Neuroimmunol 1995;63:193-205.
47. Li HL, Liu JQ, Bai XF, Van Der Meide PH, Link H. Dose-dependent mechanisms relate to nasal tolerance induction and protection against experimental autoimmune encephalomyelitis in Lewis rats. Immunology 1998;94:431-7.
48. Hofstetter HH, Ibrahim SM, Koczan D etal. Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis. Cell Immunol 2005;237:123-30.
49. Tigno-Aranjuez JT, Jaini R, Tuohy VK, Lehmann PV, Tary-Lehmann M. Encephalitogenicity of complete Freund's adjuvant relative to CpG is linked to induction of Th17 cells. J Immunol 2009;183:5654-61.
50. Skundric DS. Experimental models of relapsing-remitting multiple sclerosis: current concepts and perspective. Curr Neurovasc Res 2005;2:349-62.
51. Slavin A, Ewing C, Liu J, Ichikawa M, Slavin J, Bernard CC. Induction of a multiple sclerosis-like disease in mice with an immunodominant epitope of myelin oligodendrocyte glycoprotein. Autoimmunity 1998;28:109-20.
52. Swanborg RH. Experimental autoimmune encephalomyelitis in the rat: lessons in T-cell immunology and autoreactivity. Immunol Rev 2001;184:129-35.
53. Rooman R, Koster G, Bloemen R, Gresnigt R, Van Buul-Offers SC. The effect of dexamethasone on body and organ growth of normal and IGF-II-transgenic mice. J Endocrinol 1999;163:543-52.
54. Rauchhaus U, Schwaiger FW, Panzner S. Separating therapeutic efficacy from glucocorticoid side-effects in rodent arthritis using novel, liposomal delivery of dexamethasone phosphate: long-term suppression of arthritis facilitates interval treatment. Arthritis Res Ther 2009;11:R190.
55. Miljković D, Dekanski D, Miljković Z, Momcilović M, Mostarica-Stojkovic M. Dry olive leaf extract ameliorates experimental autoimmune encephalomyelitis. Clin Nutr 2009;28:346-50.
56. Du C, Khalil MW, Sriram S. Administration of dehydroepiandrosterone suppresses experimental allergic encephalomyelitis in SJL/J mice. J Immunol 2001;167:7094-101.
57. Offner H, Zamora A, Drought H etal. A synthetic androstene derivative and a natural androstene metabolite inhibit relapsing-remitting EAE. J Neuroimmunol 2002;130:128-39.
58. McMahon EJ, Bailey SL, Castenada CV, Waldner H, Miller SD. Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis. Nat Med 2005;11:335-9.
59. Biondo M, Field J, Toh BH, Alderuccio F. Prednisolone promotes remission and gastric mucosal regeneration in experimental autoimmune gastritis. J Pathol 2006;209:384-91.
60. Yamamoto Y, Gaynor RB. Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest 2001;107:135-42.
61. Sorrells SF, Sapolsky RM. An inflammatory review of glucocorticoid actions in the CNS. Brain Behav Immun 2007;21:259-72.
62. Tuckermann JP, Kleiman A, McPherson KG, Reichardt HM. Molecular mechanisms of glucocorticoids in the control of inflammation and lymphocyte apoptosis. Crit Rev Clin Lab Sci 2005;42:71-104.
63. Chen X, Oppenheim JJ, Winkler-Pickett RT, Ortaldo JR, Howard OM. Glucocorticoid amplifies IL-2-dependent expansion of functional FoxP3(+)CD4(+)CD25(+) T regulatory cells in vivo and enhances their capacity to suppress EAE. Eur J Immunol 2006;36:2139-49.
64. Tischner D, Reichardt HM. Glucocorticoids in the control of neuroinflammation. Mol Cell Endocrinol 2007;275:62-70.
65. Auci DL, Reading CL, Frincke JM. Hydroxy androstene steroids and a novel synthetic analogue with reduced side effects as a potential agent to treat autoimmune diseases. Autoimmun Rev 2009;8:369-72.